Also Known As:
Campath®, Campath-1H; monoclonal anti-human lymphocyte antibody; monoclonal anti-lymphocyte antibody
Alemtuzumab recognizes and targets human lymphocytes and monocytes.
It is currently also being used in clinical trials to see if it is effective in preventing graft vs. host disease in patients who have stem cell transplantation. It does not have FDA approval for that use.
How It Is Given:
Intravenously (IV, by vein)
Side Effects:
- Abnormal blood count values
- Fever with rigors, chills, and flushing (common)
- Itching (common)
- Nausea (common) and vomiting (uncommon)
- Rapid heart beat (uncommon)
- Wheezing (uncommon)
- Local skin reaction related to swelling in capillaries (uncommon)
- Low blood pressure (uncommon)
Late side effect:
- Relapse of leukemia (uncommon)
Special Points:
- Tell your doctor if you have ever had any sensitivity reactions to a monoclonal antibody.
- You may be given medication before the infusion of alemtuzumab to help minimize the risk of an allergic reaction. Someone should always escort you home.
Call Your Doctor or Nurse If You Have:
- A fever of 100.5° F (38° C) or higher.
- Excessive vomiting.
- An inability to eat or drink.
- Difficulty breathing.
- Any questions, concerns, or any unexplained problems.
